A hypercoagulable state in sickle cell disease (SCD) and beta thalassemia has been established and thrombosis is an important aspect of the clinical spectrum of sickle cell disease. In a case-control study, the prevalence of factor V Leiden and prothrombin G20210A mutations were investigated among SCD patients from Southern Iran.Methods
Patients comprised 60 individuals with SCD; of them 35 were with sickle cell anemia (SS) including 21 males and 14 females aged 17.2 ± 8.3 years, 15 were sickle cell trait (AS) consisted of nine males and six females aged 30 ± 15.4 years and 10 were sickle/β thalassemia (S/Thal) (three males and seven females) aged 24.6 ± 10.4 years. The control group were 126 apparently healthy individuals (50 males and 76 females) aged 20.1 ± 9.8 years. Genotyping was done by polymerase chain reaction restriction fragment-length polymorphism (PCR-RFLP) using Mnl I and Hind III for factor V Leiden and prothrombin G20210A, respectively.Results
Heterozygous factor V Leiden mutation was found in five of 35 (14.3%) SS patients, two of 15 (13.3%) AS individuals, one (a sickle/β-zero thalassemia patient with IVSII.1 G→A mutation) of 10 S/Thal patients (10%), and two of 126 (1.6%) control subjects (P < 0.05). However, only one AS individual (6.7%) was found to be a carrier for prothrombin G20210A compared to five of 126 (4%) healthy individuals. Adjusted logistic regression analysis for the effects of age and sex was performed and a significant association was found between factor V Leiden mutation and sickle cell anemia with odds ratios (OR) of 6.5 (95% confidence intervals [CI] 1.19–35.33, P = 0.03) in SS patients. However, increased prevalence of the factor V Leiden in AS individuals and S/Thal patients was not statistically significant compared to controls (OR 3.84, 95% CI 0.49–29.9, P = 0.19 and OR 3.77, 95% CI 0.31–45.9, P = 0.29, respectively).Conclusions
Our findings indicate a significant correlation between factor V Leiden and sickle cell anemia among Iranian patients. Association between venous thrombophilia and factor V Leiden mutation in Iranians with sickle cell anemia should be further studied.